Citadel Advisors
CMPX icon

Citadel Advisors’s Compass Therapeutics CMPX Stock Holding History

Citadel Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.82M Buy
3,570,674
+2,849,264
+395% +$8.41M ﹤0.01% 3965
2026
Q1 		$3.82M Buy
721,410
+615,728
+583% +$3.55M ﹤0.01% 4799
2025
Q4 		$568K Sell
105,682
-127,589
-55% -$589K ﹤0.01% 8718
2025
Q3 		$816K Buy
+233,271
New +$737K ﹤0.01% 7985
2024
Q4 		– Sell
-64,226
Closed -$118K – 14610
2024
Q3 		$118K Sell
64,226
-203,546
-76% -$254K ﹤0.01% 10904
2024
Q2 		$268K Buy
267,772
+123,587
+86% +$180K ﹤0.01% 9358
2024
Q1 		$285K Sell
144,185
-21,952
-13% -$37.9K ﹤0.01% 9556
2023
Q4 		$259K Buy
+166,137
New +$287K ﹤0.01% 9449
2023
Q2 		– Sell
-44,460
Closed -$145K – 14432
2023
Q1 		$145K Sell
44,460
-17,816
-29% -$69.9K ﹤0.01% 10687
2022
Q4 		$313K Buy
+62,276
New +$248K ﹤0.01% 9224
2022
Q1 		– Sell
-33,573
Closed -$106K – 13692
2021
Q4 		$106K Buy
+33,573
New +$111K ﹤0.01% 12659

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's CMPX Position: Q2 2026 in Review

Citadel Advisors increased its Compass Therapeutics (CMPX) stake by 395% in Q2 2026, buying an estimated $8.41M and bringing the position to 3,570,674 shares worth $7.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3965.

Citadel Advisors first reported a position in CMPX in Q4 2021 and has held it in 11 quarters since. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Citadel Advisors held 3,570,674 shares of Compass Therapeutics worth $7.82M as of Q2 2026.
  • Citadel Advisors bought 2,849,264 Compass Therapeutics shares in Q2 2026, an estimated $8.41M.
  • Compass Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3965 holding.
  • Citadel Advisors first reported a position in Compass Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.